Immunology companies study and manipulate the immune system to develop therapies, diagnostics and research tools. The field plays a central role in areas such as cancer, infectious disease, autoimmune disorders and vaccine development.
This category includes companies working on:
Browse 182 UK immunology companies below.
Glycan-based biological age and inflammaging diagnostics
GlycanAge is a biotechnology company that develops and sells diagnostic tests based on IgG glycan biomarkers. Its flagship product analyses glycans from a finger-prick blood sample to determine a customer's biological age, reflecting the degree of chronic inflammation driving immune ageing. Tests are available…
Oral delivery platform for biologics targeting inflammatory diseases
Intract Pharma is a biotechnology company developing proprietary formulation platforms for the oral delivery of complex biologics including monoclonal antibodies and proteins. The technology enables precision delivery to the colon for local and systemic immunomodulation, targeting gastrointestinal and systemic…
Topical formulations treating atopic dermatitis and inflammatory skin disease
Quodria is a dermatology-focused biotech developing novel topical formulations for skin diseases using nanotechnology-enabled drug delivery. Its lead programme, Q001, is a small molecule galectin-3 inhibitor licensed from University of Liverpool spin-out Galytx, in development as a first-in-class topical treatment for…
Shark-derived single-domain antibody biologics for cancer and inflammation
Elasmogen is a biotechnology company developing next-generation therapeutic biologics based on its proprietary soloMER platform, single-domain antibody-like proteins derived from the shark immune system. soloMERs offer advantages over conventional antibodies in size, stability, and tissue penetration. The pipeline…
Biparatopic PD-1/VEGFR2 antibody for solid tumour oncology
Ottimo Pharma is a clinical-stage biotechnology company developing biparatopic antibody therapeutics for solid tumour cancers. Its lead programme, Jankistomig, is a first-in-class single-agent IgG antibody that simultaneously targets PD-1 for immune checkpoint inhibition and VEGFR2 to suppress tumour angiogenesis. The…
Immunotherapies targeting blood cancer precursor conditions before onset
Athernal Bio is a Cambridge-based biotechnology company developing targeted immunotherapies for high-risk clonal haematopoiesis, a widespread blood stem cell mutation condition that significantly increases the risk of acute myeloid leukaemia and other haematological cancers. The company's pipeline comprises three…
Preclinical vaccines targeting antimicrobial-resistant bacterial infections
VacTimmune is a biotechnology company developing preventative vaccines against bacterial pathogens associated with antimicrobial resistance. Its preclinical pipeline includes candidates targeting Pseudomonas aeruginosa, Klebsiella pneumoniae and other clinically important bacteria, with an emphasis on infections…
Academic drug discovery accelerator developing small molecule therapeutics
Slingshot Therapeutics is a drug discovery accelerator that identifies early-stage scientific programmes from academic institutions and advances them towards clinical development. The company provides centralised expertise, operational infrastructure, and funding to progress small molecule candidates through…
T-cell immune profiling diagnostics and immunology research reagents
Virax Biolabs develops diagnostic tests that measure T-cell immune responses to viral infections. Its lead assay focuses on post-acute infection syndromes, including long COVID, and is intended to help characterise patients' cellular immune responses. The company also supplies immunology research reagents, including…
TCR therapeutic discovery platform targeting solid tumours
T-Cypher Bio is a pre-clinical biotechnology company developing T-cell receptor therapeutics using its proprietary platform, which integrates immunopeptidomics, bead-display microfluidics, and immune synapse mapping to identify novel intracellular targets and potent TCRs directly from patient tissue. The approach…
Pharmaceutical company in cardiometabolic, oncology, and immunology
Eli Lilly and Company is a multinational pharmaceutical company with UK operations headquartered in Basingstoke and an R&D site in Bracknell. Founded in 1876, Lilly's UK affiliate has operated since 1934 and employs approximately 700 people across regulatory, medical affairs, and research functions. The company…
Somatic genomics for genetically validated drug target discovery
Quotient Therapeutics is a biotechnology company developing medicines from genetic differences between cells within the same person. Its somatic genomics platform combines sensitive DNA sequencing, cell analysis and computational biology to identify mutations linked to disease resistance or susceptibility. These…
Oral small-molecule therapies targeting autoimmune disease pathways
SMIN Therapeutics is a biotechnology company developing oral medicines for autoimmune diseases. Its drug discovery platform studies interactions between proteins to identify therapeutic compounds, with an initial focus on the neonatal Fc receptor (FcRn), which regulates immunoglobulin G (IgG). The company is…
Macrophage-based reprogramming of the innate immune system
Ojas Immune develops therapies that reprogramme macrophages, innate immune cells involved in inflammation, tissue repair and disease. Its platforms combine synthetic biology, stem cell engineering and computational modelling. SyntheMacs focuses on engineered macrophage cell therapies, while ReProMacs explores…
Small molecule theranostics to improve transplant outcomes
Kairos Biotech is an early-stage biotechnology company developing proprietary small molecules and nanoscale-engineered binders for application in transplant diagnostics and targeted immunotherapy. The company's theranostic approach identifies molecules capable of detecting donor-specific alloreactivity and further…
Defined live bacterial consortia for oncology and inflammatory bowel disease
Microbiotica is a clinical-stage biopharmaceutical company developing oral live biotherapeutic products comprising defined consortia of gut commensal bacterial strains. Candidate bacterial strains are identified by analysing microbiome data from clinical outcome studies, enabling mechanistically grounded strain…
Distributor of antibodies and reagents for life science research
Stratech Scientific was a UK distributor of life science research products, including antibodies, reagents, cells and specialist laboratory supplies used in immunology, cell biology, cancer research and neuroscience. On 24 February 2026, Cambridge Bioscience acquired the business. Stratech's products and customer…
Generic, branded and biosimilar medicines across global therapeutic areas
Viatris UK Healthcare is the UK subsidiary of Viatris Inc., a global pharmaceutical company formed in 2020 through the combination of Mylan and Pfizer's Upjohn division. Operating from sites in Hertfordshire, Cambridge, and Sandwich, Kent, the UK entity carries out formulation and device research and development,…
Global influenza vaccine leader with major UK manufacturing in Liverpool
CSL Seqirus is one of the world's largest influenza vaccine companies, operating the only injectable influenza vaccine manufacturing facility in the UK at Speke, Liverpool. The site employs more than 650 people and produces egg-based and cell culture-derived influenza vaccines for seasonal and pandemic use, with surge…
Dark genome platform identifying first-in-class targets for autoimmune disease
Nucleome Therapeutics is a drug discovery company using 3D genome mapping to identify therapeutic targets encoded in the non-coding regions of the human genome. Its platform integrates high-resolution chromatin conformation data with functional genomics and machine learning to link disease-associated genetic variants…